Table 1.

Baseline characteristics of study participants.

	Total (n = 30)	Relapsing (n = 17)	Non-relapsing (n = 13)	P-value
Demographics
Age (yrs)	11.6 ± 6.9	11.1 ± 6.7	12.3 ± 7.4	0.65
Sex n (%)				0.24
Female	6 (20)	2 (12)	4 (31)
Male	24 (80)	15 (88)	9 (69)
Treatment				0.29
Rituximab n (%)	15 (50)	10 (59)	5 (38)
Ofatumumab n (%)	15 (50)	7 (41)	8 (62)
Prior rituximab use, n (%)	12 (40)	6 (35)	6 (46)	0.36
Number of prior relapses, n	1.5 (1-10)	2 (1-10)	1 (1-6)	0.52
Immunosuppressive drugs at enrollment (T0), n (%)
Steroids	30 (100)	17 (100)	13 (100)	1.0
Tac	16 (53)	9 (53)	7 (58)	0.96
CsA	13 (43)	8 (47)	5 (38)	0.63
Labs
Serum Creatinine (mg/dL)	0.54 ± 0.24	0.53 ± 0.27	0.55 ± 0.20	0.85
Serum Albumin (g/dL)	3.73 ± 0.64	3.74 ± 0.55	3.71 ± 0.77	0.88
Cholesterol (mg/dL)	210 ± 61	192 ± 57	232 ± 61	0.09
eGFR (ml/min)	137 ± 38	142 ± 39	129 ± 37	0.35
IgA (mg/dL)	658 ± 231	638 ± 243	685 ± 221	0.59
IgM (g/dL)	166 ± 109	162 ± 127	171 ± 84	0.82
IgG (mg/dL)	144 ± 83	150 ± 99	134 ± 60	0.60
Proteinuria (mg/24 h)	99 ± 83	116 ± 104	78 ± 36	0.18

Data are mean ± SD number (%), or median (range). p-value compares the two treatment groups in a two-tailed t-test of heteroscedastic variance or chi squared. Tac, tacrolimus; CsA, cyclosporine.